Latest Articlesddd
When you do your due diligence, you do not lose your faith in what you believed …
Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, “Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances …
XOMA Announces License Agreement with Novo Nordisk for XMetA Program in Diabetes – Novo Nordisk acquires …
Prohost Letter #388 TOPICS - 1. AN INDISPENSABLE SHORT INTRODUCTION 2. GENE EDITING 3. GENE THERAPY …
In our yesterday’s article asking about how the FDA advisory committee has to vote regarding Biomarin …
Today, the FDA advisory panel will discuss BioMarin (BMRN) product drisapersen for Duchenne muscular dystrophy based on documents released …
Europe Approves Orkambi® The European Commission has granted Marketing Authorization for Orkambi® (lumacaftor/ivacaftor), for cystic fibrosis …
When we hear about a new approach that promises bringing in hopefulness in patients diagnosed with …
Food allergies are bad, significant, dangerous and growing in the U.S. and the rest of the …
Exelixis (EXEL) received the first of the great news we expected to hear. Today, the U.S. Food …
Prohost Letter #387 Topic of the Week DUCHENNE MUSCULAR DYSTROPHY Which Firms Will Get It Right …
To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say …
– Shire to Acquire Dyax for $5.9million and some possible extras. – Angioedema market has treatments …
Prohost Letter #386 An Evaluation of Prohost Picks and Some Other Interesting Biotechnology Companies (Part 2) …
Another Durable Botulinum Toxin with Many Advantages REVANCE THERAPEUTICS As per its self- described profile, Revance …
POSITIVE TOP-LINE RESULTS FROM A PHASE 2 TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH CHRONIC HEART FAILURE …
The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious …
– Exelixis submitted rolling NDA for cabozantinib. – Exelixis plans to complete the submission in the …
Prohost Letter #385 An Evaluation of Prohost Picks and Some Other Interesting Biotechnology Companies The Top-Tier …
About Duchenne muscular Dystrophy treatments, bloggers tried to explain the reasons that led the FDA to …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
